Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

Tremelimumab, a cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody, did not significantly prolong overall survival in patients with previously treated malignant mesothelioma when ...

September 16, 2024--(BUSINESS WIRE)--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) plus IMJUDO ® (tremelimumab-actl) demonstrated a sustained ...

If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Tremelimumab given at two dosing regimens afforded durable tumor responses in patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single ...

In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

The approval was based on data from a phase 3 POSEIDON study. The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with Imfinzi (durvalumab) and platinum ...

28 March 2024 In progress. Please note that following on from advice received from the company this topic has now been scheduled back into the work programme. We now anticipate that the appraisal will ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...

It’s been a long road, but Astrazeneca plc’s anti-CTLA4 antibody, tremelimumab, finally earned its first U.S. FDA nod, cleared for use in combination with anti-PD-L1 drug Imfinzi (durvalumab) to treat ...